- WHO meeting on Wednesday will determine whether Covaxin can receive Emergency Use Listing.
- Ocugen owns rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
- OCGN stock rose 12.1% on Tuesday in anticipation.
Update after Wednesday close: Ocugen (OCGN) closed Wednesday down nearly 15% at $13.37 after another tumulotous session. the stock surged as high as $17.65 before sliding as the afternoon wore on. It appears to have been a case of buy the rumour sell the fact as the WHO confirmed its approval for Covaxin. This had been rumoured for some time and social media mentions of OCGN had been rising.
UPDATE: WHO approved the India-based Bharata Biotech's Covaxin vaccine for an Emergency Use Listing that will allow it to be purchased and donated to the COVAX facility that distributes vaccines worldwide through the Vaccine Alliance. Ocugen has the rights to distribute it in the US and Canada. The stock is down 5.7% at $14.77 in Wednesday's session.
Ocugen (OCGN) jumped 12.1% to close at $15.67 on Tuesday, just one day after it bounced by 18.1% to $13.98. The entirety of the OCGN price rise is anticipation for today, Wednesday, November 3, when the World Health Organization (WHO) is expected to have its final technical meeting concerning the efficacy of a COVID-19 vaccine designed by one of Ocugen's partners. The stock was down 4.8% on Wednesday's premarket at $14.92.
OCGN News: All about Covaxin
The day has come. A technical advisory panel from the WHO is slated to determine whether India-based Bharat Biotech's Covaxin vaccine has all the necessary data to be given an Emergency Use Listing (EUL). The EUL would allow Covaxin to be used in the COVAX Facility, which distributes COVID-19 vaccines to hundreds of nations.
If Covaxin is approved, it will greatly benefit Bharat, a private company, but will it benefit OCGN stock? Ocugen only owns the rights to distribute the vaccine in the US and Canada, and those nations are donors rather than beneficiaries of the COVAX Facility.
Of course, maybe the approval of the drug for a EUL signifies a greater likelihood that regulators in the US and Canada will approve Covaxin for their own citizens. The more significant future dates for OCGN shareholders are when Canada approves its application to distribute it there, and if or when the US Food & Drug Administration approves its phase-3 study. Both of those dates are uncertain, however, so the current market focus on the WHO is the only news to trade on.
Bharat Biotech submitted its forms for EUL listing on April 19. The first meeting with the WHO on October 26 ended with the organization asking Bharat to submit additional information and data. The Technical Advisory Group for Emergency Use Listing is actually an independent advisory commission organized under the aegis of the WHO.
OCGN key statistics
Market Cap | $2.8 billion |
Price/Earnings | N/A |
Price/Sales | N/A |
Price/Book | 20.2 |
Enterprise Value | $2.2 billion |
Gross Margin | N/A |
Net Margin |
N/A |
52-week high | $18.77 |
52-week low | $0.27 |
Short Interest | 28.7% |
Average Wall Street Rating and Price Target | Hold $8.88 |
OCGN Stock Chart: A day of reckoning for traders
Just as we had predicted, the stock closed at resistance on Tuesday at $15.67. From Tuesday's piece: "At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail."
Ocugen is a stock that has trended down for years and has lost as much as 99% of its value since its IPO in 2014. It traded for pennies in 2020 but is up more than 600% this year.
The target for longs remains $16.20, the high on May 3. After that, the next line in the sand is $18.77. With the stock already down some 4% in the premarket on Wednesday, however, we think it likely is that many in the market have already decided to sell the news. If the stock is not able to break through the current resistance zone and $16.20, then it will likely trade down as far as the 9-day moving average at $10.76.
FXStreet View: The advice stays the same: sell the news. From Tuesday's article: "No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past." If you are holding on Wednesday, now is the time to book profits. This will then allow you to buy back in at a lower price before the decisions by US and Canadian regulators.
OCGN daily chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: Next on the downside comes 0.6500
Further gains in the US Dollar kept the price action in commodities and the risk complex depressed on Tuesday, motivating AUD/USD to come close to the rea of the November low near 0.6500.
EUR/USD: No respite to the sell-off ahead of US CPI
The rally in the Greenback remained well and sound for yet another session, weighing on the risk-linked assets and sending EUR/USD to new 2024 lows in the vicinity of 1.0590 prior to key US data releases.
Gold struggles to retain the $2,600 mark
Following the early breakdown of the key $2,600 mark, prices of Gold now manages to regain some composure and reclaim the $2,600 level and beyond amidst the persistent move higher in the US Dollar and the rebound in US yields.
SOL Price Forecast: Solana bulls maintain $250 target as Binance lists ACT and PNUT
Solana price retraced 7% from $225 to $205 on Tuesday, halting a seven-day winning streak that saw SOL become the third-largest cryptocurrency by market capitalization.
Five fundamentals: Fallout from the US election, inflation, and a timely speech from Powell stand out Premium
What a week – the US election lived up to their hype, at least when it comes to market volatility. There is no time to rest, with politics, geopolitics, and economic data promising more volatility ahead.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.